Dose‐Related Safety and Immunogenicity of a Trivalent Baculovirus‐Expressed Influenza‐Virus Hemagglutinin Vaccine in Elderly Adults
| Autor: | Rebecca C. Brady, Gilbert M. Schiff, Thomas R. Cate, Mark Wolff, Manon M.J. Cox, John J. Treanor, C. Mhorag Hay, Dewei She, Robert B. Couch |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Maximum Tolerated Dose Influenza vaccine Orthomyxoviridae Dose-Response Relationship Immunologic Hemagglutinin (influenza) Hemagglutinin Glycoproteins Influenza Virus Antibodies Viral medicine.disease_cause Virus Influenza A virus medicine Humans Immunology and Allergy Elderly adults Aged Aged 80 and over biology Immunogenicity Middle Aged biology.organism_classification Virology Infectious Diseases Vaccines Inactivated Influenza Vaccines Immunology biology.protein Female Intramuscular injection Baculoviridae |
| Zdroj: | The Journal of Infectious Diseases. 193:1223-1228 |
| ISSN: | 1537-6613 0022-1899 |
| DOI: | 10.1086/503050 |
| Popis: | BACKGROUND Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. METHODS In a randomized, double-blind trial conducted in 399 adults > or = 65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 microg, 45 microg, or 135 microg of each HA. RESULTS Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 microg or 135 microg of each HA. CONCLUSIONS Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|